uniQure (NASDAQ:QURE) Insider Walid Abi-Saab Sells 1,350 Shares

uniQure (NASDAQ:QURE) insider Walid Abi-Saab sold 1,350 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $13,891.50. Following the completion of the sale, the insider now directly owns 151,903 shares of the company’s stock, valued at $1,563,081.87. The trade was a 0.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

uniQure Trading Up 6.7 %

Shares of NASDAQ:QURE opened at $12.09 on Thursday. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The stock has a market cap of $589.30 million, a price-to-earnings ratio of -2.44 and a beta of 0.38. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a 50-day moving average price of $14.69 and a 200-day moving average price of $9.91.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wells Fargo & Company reduced their price objective on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Mizuho boosted their price target on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a research note on Tuesday. Leerink Partners boosted their price objective on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Finally, Guggenheim restated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $38.89.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Voloridge Investment Management LLC acquired a new stake in uniQure in the fourth quarter valued at approximately $3,129,000. Woodline Partners LP acquired a new stake in shares of uniQure in the fourth quarter worth approximately $2,484,000. Two Sigma Advisers LP boosted its stake in shares of uniQure by 1.4% in the fourth quarter. Two Sigma Advisers LP now owns 756,900 shares of the biotechnology company’s stock worth $13,367,000 after acquiring an additional 10,400 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of uniQure by 9.2% in the fourth quarter. Two Sigma Investments LP now owns 878,884 shares of the biotechnology company’s stock worth $15,521,000 after acquiring an additional 73,988 shares during the last quarter. Finally, Stempoint Capital LP acquired a new stake in shares of uniQure in the fourth quarter worth approximately $1,589,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.